Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504550 | 1.00 | KDM4E (0.38) | KDM4ECA2PTGS1MMP12NFKB1 | |
| SCHEMBL383606 | 0.88 | HDAC8 (0.36) | KDM4ECA2PTGS1MMP12HDAC1 | |
| SCHEMBL27905560 | 0.84 | CCR2 (0.40) | CA2HDAC1 | |
| SCHEMBL2350820 | 0.82 | — | — | |
| SCHEMBL9814623 | 0.79 | NFKB1 (0.30) | NFKB1TRPA1 | |
| SCHEMBL6682186 | 0.77 | GRIK1 (0.35) | KDM4ECA2PTGS1MMP12 | |
| SCHEMBL627893 | 0.77 | KDM4E (0.32) | KDM4ECA2PTGS1MMP12HDAC1 | |
| SCHEMBL1172931 | 0.75 | — | — | |
| SCHEMBL628574 | 0.69 | HDAC8 (0.44) | HDAC1 | |
| SCHEMBL129059 | 0.69 | CD81 (0.44) | KDM4EPTGS1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114392040-A | Systems and methods for delivering therapeutic agents | 特清公司 | 2022-04-26 | — | — | CN | disclosed |
| US-8133512-B2 | Drug delivery systems based on catonic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133511-B2 | Drug delivery system based on cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090274745-A1 | Drug delivery systems based on catonic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274744-A1 | Drug delivery system based on cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-7579021-B2 | Drug delivery systems based on degradable cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080075780-A1 | Drug delivery systems based on degradible cationic siloxanyl macromonomers | SANTARUS, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274744-A1 | Drug delivery system based on cationic siloxanyl macromonomers | MSR1, LPXN, SRRM2 | KDM4E 2162/4885CA2 2079/4885PTGS1 1601/4885 |
| US-20090274745-A1 | Drug delivery systems based on catonic siloxanyl macromonomers | MMP13, LPXN, SLC13A2 | KDM4E 2807/4885CA2 601/4885PTGS1 1353/4885 |
| US-20080075780-A1 | Drug delivery systems based on degradible cationic siloxanyl macromonomers | MSR1, LPXN, SRRM2 | KDM4E 2107/4885CA2 1777/4885PTGS1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.